Quan Nguyen
Optometrist · Houston, TXNPI 1144584400
Payments from drug & device makers
Across 86 payments — averaging $56.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Visioneering Technologies, Inc.$1K
- Alcon$471
- Optos, Inc.$438
- Sun Pharmaceutical Industries Inc.$380
- Bausch & Lomb Americas Inc.$330
- Bausch & Lomb, A Division Of Bausch Health US, LLC$302
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,53493%
- Entertainment$3407%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Visioneering Technologies, Inc. | 3 | $1,318 |
| Alcon | 9 | $471 |
| Optos, Inc. | 5 | $438 |
| Sun Pharmaceutical Industries Inc. | 11 | $380 |
| Bausch & Lomb Americas Inc. | 14 | $330 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $302 |
| Tarsus Pharmaceuticals, Inc. | 5 | $154 |
| Coopervision Inc. | 2 | $153 |
| Glaukos Corporation | 2 | $138 |
| Carl Zeiss Meditec USA, Inc. | 1 | $123 |
| Dompe US, Inc. | 1 | $121 |
| LKC Technologies, Inc. | 1 | $119 |
| Novartis | 5 | $113 |
| Biotissue Holdings Inc. | 1 | $104 |
| AbbVie(2 entities) | 4 | $102 |
| Quidel Corporation | 1 | $98 |
| Aerie Pharmaceuticals, Inc. | 1 | $91 |
| Johnson & Johnson Vision Care, Inc. | 3 | $90 |
| Harrow Eye, LLC | 2 | $55 |
| Kala Pharmaceuticals, Inc. | 3 | $50 |
| Oyster Point Pharma, Inc. | 2 | $49 |
| Shire North American Group Inc | 2 | $42 |
| Sight Sciences, Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANORAMIC OPHTHALMOSCOPE$278
- OCT OPHTHALMOSCOPE$278
- TOTAL30$246
- NFC-700$139
- iDoseTR$125
- Oxervate$121
- MiSight Contact Lens$115
- ALDEN SCLERAL ZENLENS$109
- Precision7$107
- DAILIES TOTAL1$107
- Precision 1$107
- Systane$105
- Opti-Free$105
- Clear Care$105
- Freshlook$105
- DAILIES$105
- P200DTx$105
- P200T$105
- P200TE$105
- P200TxE$105
How this compares
$4,875 in reported general payments places this provider in the 90th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 313 | $340,932 |
| XiidraLifitegrast | 179 | $235,896 |
| LumiganBimatoprost | 68 | $45,932 |
| Cyclosporine | 49 | $21,824 |
| VyzultaLatanoprostene Bunod | 23 | $10,050 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $6,224 |
| Travoprost | 18 | $1,466 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 44 | $1,251 |
| Azelastine Hcl | 299 | $1,241 |
| Latanoprost | 241 | $994 |
| Prednisolone Acetate | 74 | $731 |
| ErythromycinErythromycin Base | 70 | $488 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 37 | $275 |
| Timolol Maleate | 39 | $82 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $102 | $393,088401 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $330 | $245,946202 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Houston
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
- Kathryn RichdaleHouston$288K
- Nancy StephensHouston$241K
- Jelita Green-DathorneHouston$232K
- Eric RitcheyHouston$151K
- Maria WalkerHouston$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.